ECSP21040300A - Composiciones sinérgicas que comprenden (r)-2-(2-oxopirrolidin-1-il)butanamida y (s)-2-(2-oxopirrolidin-1-il)butanamida en una proporción no racémica - Google Patents

Composiciones sinérgicas que comprenden (r)-2-(2-oxopirrolidin-1-il)butanamida y (s)-2-(2-oxopirrolidin-1-il)butanamida en una proporción no racémica

Info

Publication number
ECSP21040300A
ECSP21040300A ECSENADI202140300A ECDI202140300A ECSP21040300A EC SP21040300 A ECSP21040300 A EC SP21040300A EC SENADI202140300 A ECSENADI202140300 A EC SENADI202140300A EC DI202140300 A ECDI202140300 A EC DI202140300A EC SP21040300 A ECSP21040300 A EC SP21040300A
Authority
EC
Ecuador
Prior art keywords
oxopyrrolidin
butanamide
proportion
racemic
composition
Prior art date
Application number
ECSENADI202140300A
Other languages
English (en)
Inventor
Cesare Mannelli Lorenzo Di
Carla Ghelardini
Michael Scherz
Carlo Farina
Original Assignee
Metys Pharmaceuticals AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metys Pharmaceuticals AG filed Critical Metys Pharmaceuticals AG
Publication of ECSP21040300A publication Critical patent/ECSP21040300A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente invención se refiere a una composición de los enantiómeros de 2-(2-oxopirrolidin-1-il)butanamida y solvatos o co-cristales farmacéuticamente aceptables de la misma en una cierta proporción, una composición farmacéutica que comprende dicha composición, su uso como un medicamento y el uso de las composiciones o composiciones farmacéuticas inventivas en el tratamiento y/o prevención de una enfermedad o trastorno seleccionado generalmente y preferiblemente de trastornos relacionados con las convulsiones, neuropatía sensorial periférica, preferiblemente dolor neuropático periférico; convulsiones; depresión; o deterioro cognitivo.
ECSENADI202140300A 2018-12-04 2021-06-03 Composiciones sinérgicas que comprenden (r)-2-(2-oxopirrolidin-1-il)butanamida y (s)-2-(2-oxopirrolidin-1-il)butanamida en una proporción no racémica ECSP21040300A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18210106 2018-12-04

Publications (1)

Publication Number Publication Date
ECSP21040300A true ECSP21040300A (es) 2021-07-30

Family

ID=64604549

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202140300A ECSP21040300A (es) 2018-12-04 2021-06-03 Composiciones sinérgicas que comprenden (r)-2-(2-oxopirrolidin-1-il)butanamida y (s)-2-(2-oxopirrolidin-1-il)butanamida en una proporción no racémica

Country Status (20)

Country Link
US (1) US20220047548A1 (es)
EP (1) EP3890833B1 (es)
JP (1) JP2022510363A (es)
KR (1) KR20210099567A (es)
CN (1) CN113164767A (es)
AU (1) AU2019391309A1 (es)
BR (1) BR112021010739A2 (es)
CA (1) CA3117350A1 (es)
CO (1) CO2021007055A2 (es)
EA (1) EA202191485A1 (es)
EC (1) ECSP21040300A (es)
ES (1) ES2953785T3 (es)
HU (1) HUE062575T2 (es)
IL (1) IL283441A (es)
JO (1) JOP20210082A1 (es)
MX (1) MX2021006243A (es)
PL (1) PL3890833T3 (es)
SG (1) SG11202105863PA (es)
WO (1) WO2020115093A1 (es)
ZA (1) ZA202102701B (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8412358D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
EP1034826A1 (en) 1999-03-05 2000-09-13 Reuter Chemische Apparatebau Co-crystallization process
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
ITMI20030573A1 (it) 2003-03-24 2004-09-25 Nikem Research Srl Composti ad azione nootropica, loro preparazione,
CA2488325C (en) * 2004-11-22 2010-08-24 Apotex Pharmachem Inc. Improved process for the preparation of (s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide and (r)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide
EP2215073A4 (en) 2007-10-31 2011-04-06 Merck Sharp & Dohme SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS
PL2098526T3 (pl) 2008-02-22 2014-06-30 Neurotune Ag Bicykliczne związki zawierające azot aktywne w stanach przewlekłego bólu
EP2671858A1 (en) * 2012-06-08 2013-12-11 Université Catholique De Louvain Process for chiral resolution of etiracetam
JOP20190251A1 (ar) * 2017-05-31 2019-10-21 Metys Pharmaceuticals AG تركيبات تآزرية تشتمل على (r)-ديميراسيتام (1) و(s)-ديميراسيتام (2) بنسبة غير راسيمية

Also Published As

Publication number Publication date
ES2953785T3 (es) 2023-11-16
AU2019391309A1 (en) 2021-05-20
HUE062575T2 (hu) 2023-11-28
WO2020115093A1 (en) 2020-06-11
EP3890833B1 (en) 2023-06-07
US20220047548A1 (en) 2022-02-17
EP3890833A1 (en) 2021-10-13
EA202191485A1 (ru) 2021-08-30
JP2022510363A (ja) 2022-01-26
BR112021010739A2 (pt) 2021-08-24
KR20210099567A (ko) 2021-08-12
ZA202102701B (en) 2023-10-25
SG11202105863PA (en) 2021-07-29
CO2021007055A2 (es) 2021-06-10
MX2021006243A (es) 2021-08-11
EP3890833C0 (en) 2023-06-07
CA3117350A1 (en) 2020-06-11
JOP20210082A1 (ar) 2023-01-30
CN113164767A (zh) 2021-07-23
PL3890833T3 (pl) 2023-09-18
IL283441A (en) 2021-07-29

Similar Documents

Publication Publication Date Title
CL2021000382A1 (es) Compuestos novedosos de sulfonamidaurea
ECSP22052564A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
ECSP20003147A (es) Carboxamidas como moduladores de los canales de sodio
CL2011002766A1 (es) Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras.
AR079208A2 (es) Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
BR112022010754A2 (pt) Análogos de rapamicina e usos dos mesmos
CL2019003572A1 (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
ECSP19085426A (es) Composiciones sinérgicas que comprenden dimiracetam (r) (1) y dimiracetam (s) (2) en una proporción no racémica
ECSP21040300A (es) Composiciones sinérgicas que comprenden (r)-2-(2-oxopirrolidin-1-il)butanamida y (s)-2-(2-oxopirrolidin-1-il)butanamida en una proporción no racémica
AR055107A1 (es) Furoato de n-{2-[((2s)-3-{[1-(4-clorobencil)piperidin-4-il]amino}-2-hidroxi-2-metilpropil)oxi]-4-hidroxifenil} acetamida,composiciones farmaceuticas que los contienen y usos para tratar afecciones o enfermedades donde actuan como moduladores del receptor de quimioquina 1(ccr1)
EA202000347A1 (ru) ПРОТИВО-SARS-CoV-2 ВИРУСНОЕ СРЕДСТВО АНТИПРОВИР
CL2017002229A1 (es) Inhibidores de bace1.
CO2020001881A2 (es) Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco trometamina y clorhidrato de tramadol
CO2017001076A2 (es) Composiciones farmacéuticas antihiperalgésicas, antialodínicas y antiinflamatorias que contienen pregabalina y meloxicam
CO2020001375A2 (es) Derivado de adamantilmetilamina y uso del mismo como producto farmacéutico
PH12021551239A1 (en) Synergistic compositions comprising r-2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2h)-ones and s-2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2h)-ones in a non-racemic ratio
CO2021014967A2 (es) Composiciones farmacéuticas de combinación a dosis fijas de liberación inmediata, métodos y usos de las mismas
CO2022000503A2 (es) Composiciones sólidas orales de liberación inmediata de múltiples unidades, métodos y usos de las mismas
CL2022001015A1 (es) Uso de compuestos de imidazopirimidina o imidazotriazina para prevención, alivio o tratamiento de trastornos cognitivos.
UA113233U (uk) Пероральна фіксована комбінація теноксикаму і снодійного або заспокійливого компонента
CR8612A (es) Formas de dosificacion y composiciones farmaceuticas